Nanobiotix (NASDAQ:NBTX) Reaches New 12-Month High – Still a Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $57.14 and last traded at $55.07, with a volume of 142428 shares trading hands. The stock had previously closed at $52.04.

Wall Street Analysts Forecast Growth

NBTX has been the subject of a number of recent research reports. Guggenheim boosted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. UBS Group lifted their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Finally, TD Cowen restated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $26.67.

Nanobiotix Stock Performance

The business’s 50 day moving average is $34.73 and its two-hundred day moving average is $26.56.

Nanobiotix (NASDAQ:NBTX) last released its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $3.42 million for the quarter. As a group, research analysts expect that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NBTX. Millennium Management LLC purchased a new stake in Nanobiotix in the 4th quarter worth $390,000. Marshall Wace LLP bought a new position in shares of Nanobiotix during the 4th quarter valued at about $220,000. Optiver Holding B.V. bought a new position in shares of Nanobiotix during the 3rd quarter valued at about $101,000. Finally, Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.